A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells

Sci Rep. 2019 Aug 19;9(1):12031. doi: 10.1038/s41598-019-48461-1.

Abstract

Harnessing complement-mediated cytotoxicity by therapeutic antibodies has been limited because of dependency on size and density of antigen, structural constraints resulting from orientation of antibody binding, and blockade of complement activation by inhibitors expressed on target cells. We developed a modular bispecific antibody platform that directs the complement-initiating protein C1q to target cells, increases local complement deposition and induces cytotoxicity against target antigens with a wide-range of expression. The broad utility of this approach to eliminate both prokaryotic and eukaryotic cells was demonstrated by pairing a unique C1q-recruiting arm with multiple targeting arms specific for Staphylococcus aureus, Pseudomonas aeruginosa, B-cells and T-cells, indicating applicability for diverse indications ranging from infectious diseases to cancer. Generation of C1q humanized mice allowed for demonstration of the efficacy of this approach to clear disease-inducing cells in vivo. In summary, we present a novel, broadly applicable, and versatile therapeutic modality for targeted cell depletion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bispecific / immunology*
  • Antibody-Dependent Cell Cytotoxicity / immunology
  • Complement Activation
  • Complement Membrane Attack Complex / metabolism
  • Complement System Proteins / immunology*
  • Cytotoxicity, Immunologic*
  • Disease Models, Animal
  • Humans
  • Mice
  • Mice, Transgenic
  • Protein Binding
  • Staphylococcal Infections / immunology
  • Staphylococcal Infections / metabolism
  • Staphylococcal Infections / microbiology
  • Staphylococcus aureus / immunology

Substances

  • Antibodies, Bispecific
  • Complement Membrane Attack Complex
  • Complement System Proteins